{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:53:11Z","timestamp":1760100791725},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"26","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1097\/md.0000000000001006","type":"journal-article","created":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T13:48:52Z","timestamp":1435758532000},"page":"e1006","source":"Crossref","is-referenced-by-count":11,"title":["Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer"],"prefix":"10.1097","volume":"94","author":[{"given":"Jiayu","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruigang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-16-20210309","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0140-6736(14)62038-9","article-title":"Global surveillance of cancer survival 1995-2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2).","volume":"385","author":"Allemani","year":"2015","journal-title":"Lancet"},{"key":"R2-16-20210309","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.canep.2009.10.003","article-title":"Breast cancer as a global health concern.","volume":"33","author":"Coughlin","year":"2009","journal-title":"Cancer Epidemiol"},{"key":"R3-16-20210309","first-page":"1949","article-title":"Risk factors for breast cancer in Chinese women in Shanghai.","volume":"48","author":"Yuan","year":"1988","journal-title":"Cancer Res"},{"key":"R4-16-20210309","first-page":"435","article-title":"A case-control study of breast cancer in Tianjin, China.","volume":"1","author":"Wang","year":"1992","journal-title":"Cancer Epidemiol"},{"key":"R5-16-20210309","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ijc.11300","article-title":"Time trends in cancer mortality in China: 1987-1999.","volume":"106","author":"Yang","year":"2003","journal-title":"Int J Cancer"},{"key":"R6-16-20210309","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/bjc.1990.344","article-title":"Sex hormones in women in rural China and in Britain.","volume":"62","author":"Key","year":"1990","journal-title":"Br J Cancer"},{"key":"R7-16-20210309","first-page":"243","article-title":"Estimates of cancer incidence in China for 2000 and projections for 2005.","volume":"14","author":"Yang","year":"2005","journal-title":"Cancer Epidemiol"},{"key":"R8-16-20210309","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1038\/sj.bjc.6601813","article-title":"Estimation and projection of the national profile of cancer mortality in China: 1991-2005.","volume":"90","author":"Yang","year":"2004","journal-title":"Br J Cancer"},{"key":"R9-16-20210309","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/jnci\/djn305","article-title":"Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis.","volume":"100","author":"Linos","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R10-16-20210309","first-page":"1558","article-title":"Etiology of hormone receptor-defined breast cancer: a systematic review of the literature.","volume":"13","author":"Althuis","year":"2004","journal-title":"Cancer Epidemiol"},{"key":"R11-16-20210309","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.","volume":"365","year":"2005","journal-title":"Lancet"},{"key":"R12-16-20210309","doi-asserted-by":"crossref","first-page":"e100159","DOI":"10.1371\/journal.pone.0100159","article-title":"A nation-wide multicenter 10-year (1999-2008) retrospective clinical study of endocrine therapy for Chinese females with breast cancer.","volume":"9","author":"Zhou","year":"2014","journal-title":"PloS One"},{"issue":"suppl 2","key":"R13-16-20210309","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1016\/j.breast.2013.07.032","article-title":"Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.","volume":"22","author":"Jankowitz","year":"2013","journal-title":"Breast"},{"key":"R14-16-20210309","first-page":"266","article-title":"Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer.","volume":"53","author":"Iveson","year":"1993","journal-title":"Cancer Res"},{"key":"R15-16-20210309","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"Breast International Group 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.","volume":"353","author":"Thurlimann","year":"2005","journal-title":"New Engl J Med"},{"key":"R17-16-20210309","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/jnci\/92.11.903","article-title":"Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study.","volume":"92","author":"Klijn","year":"2000","journal-title":"J Natil Cancer Inst"},{"key":"R18-16-20210309","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/0960-0760(90)90455-T","article-title":"Zoladex plus tamoxifen versus Zoladex alone in pre- and peri-menopausal metastatic breast cancer.","volume":"37","author":"Nicholson","year":"1990","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R19-16-20210309","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.3892\/or.2013.2312","article-title":"Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial.","volume":"29","author":"Nishimura","year":"2013","journal-title":"Oncol Rep"},{"key":"R20-16-20210309","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10549-010-1340-y","article-title":"Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer.","volume":"126","author":"Torrisi","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"R21-16-20210309","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer.","volume":"360","author":"Gnant","year":"2009","journal-title":"New Engl J Med"},{"key":"R22-16-20210309","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1142::AID-CNCR13>3.0.CO;2-5","article-title":"Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.","volume":"83","author":"Buzdar","year":"1998","journal-title":"Cancer"},{"key":"R23-16-20210309","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1055\/s-2008-1026532","article-title":"Therapy with gonadotropin releasing hormone agonists (zoladex) in premenopausal females with metastastic breast cancer.","volume":"48","author":"Kaufmann","year":"1988","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"R24-16-20210309","first-page":"717","article-title":"Clinical efficacy of leuprorelin acetate monthly depot in premenopausal patients with metastatic breast cancer.","volume":"4","author":"Untch","year":"1997","journal-title":"Oncol Rep"},{"key":"R25-16-20210309","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/bjc.1990.397","article-title":"Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival.","volume":"62","author":"Dixon","year":"1990","journal-title":"Br J Cancer"},{"key":"R26-16-20210309","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1200\/JCO.2001.19.10.2596","article-title":"Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.","volume":"19","author":"Mouridsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"R27-16-20210309","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/cncr.21163","article-title":"Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.","volume":"104","author":"Howell","year":"2005","journal-title":"Cancer"},{"issue":"suppl 6","key":"R28-16-20210309","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0959-8049(02)00287-3","article-title":"Faslodex Investigators. Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women.","volume":"38","author":"Vergote","year":"2002","journal-title":"Eur J Cancer"},{"key":"R29-16-20210309","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1016\/j.ejca.2010.08.005","article-title":"Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women.","volume":"46","author":"Cheung","year":"2010","journal-title":"Eur J Cancer"},{"key":"R30-16-20210309","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1200\/JCO.2009.24.9565","article-title":"Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.","volume":"28","author":"Carlson","year":"2010","journal-title":"J Clin Oncol"},{"key":"R31-16-20210309","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1200\/JCO.2009.26.5884","article-title":"Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.","volume":"28","author":"Park","year":"2010","journal-title":"J Clin Oncol"},{"key":"R32-16-20210309","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.","volume":"366","author":"Baselga","year":"2012","journal-title":"New Engl J Med"},{"issue":"suppl 24","key":"R33-16-20210309","first-page":"492","article-title":"Final progression-free survival analysis of BOLERO-2: a phase III trial of everolimus for postmenopausal women with advanced breast cancer.","volume":"72","author":"Piccart","year":"2012","journal-title":"Cancer research"},{"key":"R34-16-20210309","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2007.13.5822","article-title":"Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.","volume":"26","author":"Chia","year":"2008","journal-title":"J Clin Oncol"},{"key":"R35-16-20210309","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1200\/JCO.2007.14.4659","article-title":"Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.","volume":"26","author":"Paridaens","year":"2008","journal-title":"J Clin Oncol"},{"key":"R36-16-20210309","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","article-title":"Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.","volume":"30","author":"Bachelot","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000001006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:45:25Z","timestamp":1620960325000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201507010-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":35,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000001006","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}